LivaNova (NASDAQ:LIVN) Cut to “Peer Perform” at Wolfe Research

Wolfe Research cut shares of LivaNova (NASDAQ:LIVN) from an outperform rating to a peer perform rating in a report published on Wednesday morning, Marketbeat Ratings reports.

Several other research analysts have also commented on LIVN. StockNews.com raised shares of LivaNova from a “buy” rating to a “strong-buy” rating in a report on Friday, February 14th. Robert W. Baird lifted their price target on shares of LivaNova from $66.00 to $72.00 and gave the company an “outperform” rating in a report on Thursday, October 31st. Needham & Company LLC reaffirmed a “buy” rating and issued a $75.00 price target on shares of LivaNova in a report on Tuesday, January 28th. Finally, Mizuho reduced their target price on shares of LivaNova from $80.00 to $70.00 and set an “outperform” rating for the company in a research note on Thursday, October 31st. One investment analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average target price of $64.20.

LivaNova Trading Up 1.7 %

NASDAQ LIVN opened at $41.63 on Wednesday. LivaNova has a one year low of $40.37 and a one year high of $64.47. The company has a 50-day simple moving average of $47.40 and a 200-day simple moving average of $49.49. The company has a debt-to-equity ratio of 0.46, a quick ratio of 2.87 and a current ratio of 3.37. The firm has a market capitalization of $2.26 billion, a PE ratio of 99.12 and a beta of 1.00.

Insider Buying and Selling at LivaNova

In other LivaNova news, Director Francesco Bianchi sold 1,250 shares of the business’s stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $50.99, for a total transaction of $63,737.50. Following the completion of the transaction, the director now directly owns 7,522 shares of the company’s stock, valued at $383,546.78. The trade was a 14.25 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.27% of the stock is currently owned by company insiders.

Institutional Trading of LivaNova

A number of institutional investors have recently made changes to their positions in the stock. Jefferies Financial Group Inc. acquired a new stake in shares of LivaNova in the 4th quarter worth approximately $4,812,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in shares of LivaNova by 25.0% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 153,458 shares of the company’s stock worth $7,107,000 after acquiring an additional 30,718 shares during the period. Squarepoint Ops LLC lifted its stake in shares of LivaNova by 74.3% in the 4th quarter. Squarepoint Ops LLC now owns 111,449 shares of the company’s stock worth $5,161,000 after acquiring an additional 47,494 shares during the period. Two Sigma Advisers LP lifted its stake in shares of LivaNova by 148.5% in the 4th quarter. Two Sigma Advisers LP now owns 214,545 shares of the company’s stock worth $9,936,000 after acquiring an additional 128,200 shares during the period. Finally, Two Sigma Investments LP lifted its stake in shares of LivaNova by 27.2% in the 4th quarter. Two Sigma Investments LP now owns 439,582 shares of the company’s stock worth $20,357,000 after acquiring an additional 93,985 shares during the period. 97.64% of the stock is owned by institutional investors and hedge funds.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.